Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Febrero 2024 - 8:15PM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that
on February 9, 2024, the Compensation Committee of Mirum’s Board of
Directors granted inducement awards consisting of non-qualified
stock options to purchase 33,200 shares of common stock and 16,610
restricted stock units (“RSUs”) to seven new employees under
Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s
Board of Directors approved the awards as an inducement material to
the new employees’ employment in accordance with Nasdaq Listing
Rule 5635(c)(4).
Each stock option has an exercise price per share equal to
$27.98 per share, Mirum’s closing trading price on February 9,
2024, and will vest over four years, with 25% of the underlying
shares vesting on the one-year anniversary of the applicable
vesting commencement date and the balance of the underlying shares
vesting monthly thereafter over 36 months, subject to the new
employees’ continued service relationship with Mirum through the
applicable vesting dates. The RSUs will vest over three years, with
33% of the underlying shares vesting on each anniversary of the
applicable vesting commencement date, subject to the new employees’
continued service relationship with Mirum through the applicable
vesting dates. The awards are subject to the terms and conditions
of Mirum’s 2020 Inducement Plan and the terms and conditions of an
applicable award agreement covering the grant.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to transforming the treatment of rare diseases affecting
children and adults. Mirum has three available medications:
LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid)
capsules, and Chenodal® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of
cholestatic pruritus in patients with Alagille syndrome in the U.S.
(three months and older), in Europe (two months and older), and in
Canada. Mirum has also submitted LIVMARLI for approval in the U.S.
in cholestatic pruritus in PFIC patients three months of age and
older and in Europe in PFIC for patients two months of age and
older. Cholbam is FDA-approved for the treatment of bile acid
synthesis disorders due to single enzyme defects and adjunctive
treatment of peroxisomal disorders in patients who show signs or
symptoms or liver disease. Chenodal has received medical necessity
recognition by the FDA to treat patients with cerebrotendinous
xanthomatosis (CTX).
Mirum’s late-stage pipeline includes two investigational
treatments for debilitating liver diseases. Volixibat, an IBAT
inhibitor, is being evaluated in two potentially registrational
studies including the Phase 2b VISTAS study for primary sclerosing
cholangitis and Phase 2b VANTAGE study for primary biliary
cholangitis. Lastly, Chenodal has been evaluated in a Phase 3
clinical study, RESTORE, to treat patients with CTX, with positive
topline results reported in 2023.
To learn more about Mirum, visit mirumpharma.com and follow
Mirum on Facebook, LinkedIn, Instagram and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240209888242/en/
Investor Contacts: Andrew McKibben ir@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com
Media Contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Gráfica de Acción Histórica
De May 2023 a May 2024